Table 2.

Univariate analysis of overall survival and freedom from recurrence in 61 cases of locally advanced rectal cancer with neoadjuvant chemoradiotherapy.

Prognostic factor	Overall survival		Freedom from recurrence
	HR (95% CI)	p*	HR (95% CI)	p*
CXCL12 expression		0.169		0.005
negative (n=23)	1 (reference)		1 (reference)
positive (n=38)	2.494 (0.678-9.166)		7.960 (1.848-34.289)
CXCR4 expression		0.196		0.023
negative (n=32)	1 (reference)		1 (reference)
positive (n=29)	2.095 (0.683-6.432)		2.836 (1.154-6.968)
FAPα expression		0.888		0.075
negative (n=23)	1 (reference)		1 (reference)
positive (n=38)	1.083 (0.354-3.316)		2.477 (0.911-6.732)
Age at operation		0.291		0.489
≤65 (n=31)	1 (reference)		1 (reference)
>65 (n=30)	1.826 (0.597-5.589)		1.346 (0.580-3.128)
Sex		0.373		0.490
Male (n=42)	1 (reference)		1 (reference)
Female (n=19)	0.556 (0.153-2.025)		0.718 (0.281-1.838)
R score		0.749		0.209
1 (n=11)	1 (reference)		1 (reference)
2-3 (n=50)	0.809 (0.221-2.961)		2.557 (0.592-11.048)
ypTNM stage		0.121		0.021
II (n=36)	1 (reference)		1 (reference)
III (n=25)	2.419 (0.791-7.396)		2.783 (1.164-6.657)
Post-Chemotherapy		0.527		0.013
No (n=14)	1 (reference)		1 (reference)
Yes (n=47)	1.628 (0.360-7.349)		0.330 (0.137-0.794)

* Univariate Cox regression analysis; HR, hazard ratio; CI, confidence interval; CXCL12 expression, plasma membrane expression in cancer cells; CXCR4 expression, plasma membrane expression in cancer cells; FAPα expression, cytoplasmic expression in cancer cells; R score, modified Ryan scheme for tumor regression score in American Joint Committee on Cancer (AJCC) cancer staging system (8^th edition); ypTNM stage, neoadjuvant pathologic stage in American Joint Committee on Cancer (AJCC) cancer staging system (8^th edition); and post-chemotherapy, post-operative adjuvant chemotherapy